Screening for prostate cancer: Opportunities and challenges

Surgical Oncology Clinics of North America

Volumn 14, Issue 4, 2005, Pages 747-760

  Thompson, Ian M ^a   Bermejo, Carlos ^a   Hernandez, Javier ^a   Basler, Joseph A ^a   Canby Hagino, Edith ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FINASTERIDE; HORMONE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; HORMONAL THERAPY; HUMAN; MALE; MEDICAL SOCIETY; METASTASIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SMOKING; SMOKING CESSATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 26844520051     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.07.001     Document Type: Review

References (56)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10
2. E. Silverberg, C.C. Boring, and T.S. Squires Cancer statistics, 1990 CA Cancer J Clin 40 1990 9 26
3. P.A. Wingo, T. Tong, and S. Bolden Cancer statistics, 1995 CA Cancer J Clin 45 1995 8 30
4. C.M. Tangen, J.R. Faulker, and E.D. Crawford Ten-year survival in patients with metastatic prostate cancer Clin Prostate Cancer 2 2003 41 45
5. H.K. Weir, M.J. Thun, and B.F. Hankey Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control J Natl Cancer Inst 95 2003 1276 1299
6. B.E. Sirovich, L.M. Schwartz, and S. Woloshin Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 289 2003 1414 1420
7. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 3 2003 215 224
8. J.M. Unger, I.M. Thompson Jr., and M. LeBlanc Estimated impact of the Prostate Cancer Prevention Trial on population mortality Cancer 103 7 2005 1375 1380
9. I.M. Thompson, J.J. Ernst, and M.P. Gangai Adenocarcinoma of the prostate: results of routine urological screening J Urol 132 1984 690 692
10. G.W. Chodak, and H.W. Schoenberg Early detection of prostate cancer by routine screening JAMA 252 23 1984 3261 3264
11. R.J. Ablin, W.A. Soanes, and P. Bronson Precipitating antigens of the normal human prostate J Reprod Fertil 22 1970 573 574
12. Hara M, Koyanagi Y, Inoue T. et al. Some physicochemical characteristics of "seminoprotein," an antigenic component specific for human seminal plasma. Nippon Hoigaku Zasshi 1971;25:322.
13. T.S. Li, and C.G. Beling Isolation and characterization of two specific antigens of human seminal plasma Fertil Steril 24 1973 134
14. M.C. Wang, L.A. Valenzuela, and G.P. Murphy Purification of a human prostate specific antigen Invest Urol 17 1979 159 163
15. P. Guinan, R. Bhatti, and P. Ray An evaluation of prostate specific antigen in prostatic cancer J Urol 137 1987 686 689
16. T.A. Stamey, N. Yang, and A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 15 1987 909 916
17. W. Catalona, D. Smith, and T. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 17 1991 1156 1161
18. M.K. Brawer, J. Beatie, and M.H. Wener Screening for prostatic carcinoma with prostate specific antigen: results of the second year J Urol 150 1 1993 106 109
19. M.K. Brawer, M.P. Chetner, and J. Beatie Screening for prostatic carcinoma with prostate specific antigen J Urol 147 3 Pt 2 1992 841 845
20. T.Y. Wang, and T.P. Kawaguchi Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer Ann Clin Lab Sci 16 6 1986 461 466
21. W.H. Cooner, B.R. Mosley, and C.L. Rutherford Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen J Urol 143 6 1990 1146 1152
22. M.K. Terris, and T.A. Stamey Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values Br J Urol 73 1 1993 61 64
23. K.K. Hodge, J.E. McNeal, and M.K. Terris Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate J Urol 142 1989 71 75
24. J.C. Presti, J.J. Chang, and V. Bhargava The optimal systematic prostate biopsy strategy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial J Urol 163 1 2000 163 166 [discussion, 166-7]
25. J.C. Presti Jr., G.J. O'Dowd, and M.C. Miller Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study J Urol 169 1 2003 125 129
26. J.W. Moul, I.A. Sesterrhenn, and R.R. Connelly Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men JAMA 274 16 1995 1277 1281
27. K.A. McCammon, P.F. Schellhammer, and G.L. Wright Age specific PSA levels in African Americans [abstract 461] J Urol 155 1996 426
28. H.B. Carter, J.D. Pearson, and E.J. Metter Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 16 1992 2215 2220
29. H.B. Carter, J.D. Pearson, and Z. Waclawiw Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity Urology 45 4 1995 591 596
30. A.V. D'Amico, M.H. Chen, and K.A. Roehl Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2 2004 125 135
31. R. Raaijmakers, M.F. Wildhagen, and K. Ito Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam Urology 63 2 2004 316 320
32. M.C. Benson, I.S. Whang, and C.A. Olsson The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen J Urol 147 3 Pt 2 1992 817 821
33. W.J. Catalona, J.P. Richie, and J.B. deKernion Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves J Urol 152 6 Pt 1 1994 2031 2036
34. M.K. Brawer, E.A. Aramburu, and G.L. Chen The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma J Urol 150 2 Pt 1 1993 369 373
35. R.W. Veltri, and M.C. Miller Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations Urology 53 1999 736
36. W.J. Catalona, P.C. Southwick, and K.M. Slawin Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging Urology 56 2000 255
37. th edition 2002 WB Saunders Philadelphia 3055 3079
38. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter N Engl J Med 350 22 2004 2239 2246
39. I.M. Thompson, D.P. Ankerst, and C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower JAMA 294 2005 66 70
40. W. Horninger, A.P. Berger, and A. Pelzer Prostate cancer detection rate and frequency of Gleason score ≥ 7 in men with PSA levels below 3 ng/ml [abstract] J Urol 173 2005 147
41. S. Loeb, K.A. Roehl, and J.A.V. Antenor Baseline SA compared with median PSA for age group as predictor of pathologic tumor features in men < 60 years of age J Urol 173 2005 145A
42. United States Census Bureau. Census 2000 summary file 1 (SF 1). 100 percent data. Available at: http://www.census.gov/population/cen2000/phc-t9/ tab02.pdf. Accessed May 18, 2004.
43. E. DeAntoni, E.D. Crawford, and N.N. Stone Prostate cancer awareness week, 1992: a summary of key findings [review] Clin Invest Med 16 6 1993 448 457
44. E.P. DeAntoni Eight years of prostate cancer awareness week: lessons in screening and early detection. Prostate Cancer Education Council Cancer 80 9 1997 1845 1851
45. E.P. DeAntoni, E.D. Crawford, and J.E. Oesterling Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study Urology 48 2 1996 234 239
46. B.F. Hankey, E.J. Feuer, and L.X. Clegg Cancer surveillance series: interpreting trends in prostate cancer. Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates J Natl Cancer Inst 91 12 1999 1017 1024
47. J. Hernandez, and I.M. Thompson Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker Cancer 101 2004 894 904
48. American Cancer Society. Cancer facts and figures, 2004. Available at: http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf. Accessed July 18, 2005.
49. J.M. Legler, E.J. Feuer, and A.L. Potosky The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States Cancer Causes Control 9 1998 519 527
50. L.X. Clegg, F.P. Li, and B.F. Hankey Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study Arch Intern Med 162 2002 1985 1993
51. W. Horninger, A. Berger, and A. Pelzer Screening for prostate cancer: updated experience from the Tyrol study Can J Urol 12 Suppl 1 2005 7 13
52. G.L. Andriole, D.L. Levin, E.D. Crawford, and the PLCO Project Team Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial J Natl Cancer Inst 97 6 2005 433 438
53. M.J. Roobol, R. Kranse, and H.J. de Koning Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (Rotterdam) Urology 63 2 2004 309 313
54. W.A. Sakr, G.P. Haas, and B.F. Cassin The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients J Urol 150 2 Pt 1 1993 379 385
55. W.E. Grizzle, B.L. Adam, and W.L. Bigbee Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer Dis Markers 19 4-5 2004 185 195
56. O.J. Semmes, Z. Feng, and B.L. Adam Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility Clin Chem 51 1 2005 102 112